This site is intended for healthcare professionals

MHLW (Japan) approves Darvias injection to treat peripheral T cell lymphoma.-Solasia Pharma and Nippon Kayaku.

Read time: 1 mins
Published:26th Jun 2022

Solasia Pharma K.K officially announced that an organoarsenic drug “Darvias Injection 135mg” (SP-02, hereinafter Darvias) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021.


In October 2021, Nippon Kayaku Co., Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) secured a license agreement with Darvias for marketing rights in Japan.

Condition: T- cell Lymphoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.